A 24-week, double-blind, double-dummy, randomized, parallel-group study to investigate the effects of rosiglitazone (extended release tablets), donepezil, and placebo as monotherapy on cognition and overall clinical response in APOE ε4-stratified subjects with mild to moderate Alzheimer’s disease. (REFLECT-1) •To investigate the effects of daily dosing for 24 weeks with RSG XR versus placebo on cognitive function in subjects with mild to moderate Alzheimer’s disease as a function of APOE ε4 status. •To in...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A single blind, placebo-controlled, randomised study in mild to moderate Alzheimer's disease patients to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK239512, a selective histamine H3 receptor antagonist • To assess the safety and tolerability of GSK239512 in patients with mild to moderate Alzheimer’s disease on repeat dosing.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase 2, randomized, double blind, placebo controlled study to evaluate the safety and efficacy of belimumab and rituximab co-administration in subjects with primary Sjögren’s syndrome Safety and tolerability of anti-BLyS / anti-CD 20 coadministration therapy and anti-BLyS and anti-CD 20 monotherapies

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An open-label, single-arm, multicentre, Phase II study of oral lapatinib in combination with paclitaxel as first-line treatment for ErbB2-amplified metastatic breast cancer patients To evaluate overall tumour response rate (ORR) of lapatinib combined with paclitaxel in patients with ErbB2-amplified metastatic breast cancer

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects To determine the dose response and efficacy of a range of once daily doses of GSK189075 versus placebo on the change from baseline in HbA1c.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A randomised, placebo-controlled, parallel group single dose study of SB681323 in patients with active RA to investigate the CRP dose response relationship To describe the single dose response relationship of the dose range of 7.5 to 25 mg of SB-681323 on circulating serum C-Reactive Protein (CRP) levels

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719 125mcg once-daily alone and in combination with GW642444 25mcg once-daily via novel Dry Powder Inhaler (nDPI) in Subjects with Chronic Obstructive Pulmonary Disease (COPD) The objective of this study is to evaluate the safety and tolerability of GSK573719/GW642444 Inhalation Powder125/25mcg and GSK573719 Inhalation Powder 125mcg compared with placebo all administered on...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Phase II study to evaluate the efficacy, safety and pharmacodynamics of lapatinib in patients with relapsed or refractory inflammatory breast cancer Evaluation of objective response rate (complete response + partial response) to lapatinib treatment in patients with relapsed or refractory IBC whose tumours overexpress ErbB2

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study of an experimental new drug to treat diabetes To investigate the safety and efficacy of 12 weeks of daily dosing with GSK256073 in subjects with T2DM who are on metformin monotherapy. In Part B of the study ,an open label active commercial co...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A randomized, multicentre, open-label Phase III study of lapatinib in combination with trastuzumab versus lapatinib monotherapy in subjects with metastatic breast cancer whose disease has progressed on trastuzumab-containing regimens To evaluate and compare the anti-tumour activity, in terms of progression-free survival, of trastuzumab plus lapatinib versus lapatinib monotherapy in subjects with ErbB2 amplified metastatic breast c...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune